Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Bintrafusp Alfa Trial in Japan
jRCT2080223502Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Apr 2017
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
01
Overview
Phase 1, open-label, single-arm trial of bintrafusp alfa in cancer, sponsored by Merck & Co. Started Apr 2017; status: completed.
02
Drugs
bintrafusp alfa
03
Conditions
cancer
Beyond the preview
Go deeper on jRCT2080223502.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223502.